Dongming Liu

Tianjin, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Intestine-specific Faf2 depletion ameliorates obesity and metabolic dysfunction-associated steatotic liver disease by impairing lipid absorption.

Intestine-specific Faf2 depletion ameliorates obesity and metabolic dysfunction-associated steatotic liver disease by impairing lipid absorption.

Journal: International journal of biological sciences
Published: March 13, 2026

Novel Phosphatase SSU72 Drives Malignant Progression in Colorectal Cancer via PERK Thr982 Dephosphorylation Mediated Endoplasmic Reticulum Stress Inactivation.

Novel Phosphatase SSU72 Drives Malignant Progression in Colorectal Cancer via PERK Thr982 Dephosphorylation Mediated Endoplasmic Reticulum Stress Inactivation.

Journal: International journal of biological sciences
Published: December 06, 2025

Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.

Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma.

Journal: Liver cancer
Published: August 26, 2025

Decision-Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care.

Decision-Making Biomarkers Guiding Therapeutic Strategies in Hepatocellular Carcinoma: From Prediction to Personalized Care.

Journal: Cancers
Published: August 14, 2025

cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment.

cPLA2α inhibition potentiates anti-PD-1 immunotherapy in lung adenocarcinoma via remodeling tumor microenvironment.

Journal: Communications biology
Published: July 25, 2025

Morphological alterations of peridroplet mitochondria in human liver biopsy.

Morphological alterations of peridroplet mitochondria in human liver biopsy.

Journal: Scientific reports
Published: July 21, 2025

PNO1 served as a potential biomarker to promote the stemness and progression of breast cancer via the NF-κB signaling pathway.

PNO1 served as a potential biomarker to promote the stemness and progression of breast cancer via the NF-κB signaling pathway.

Journal: Stem cells (Dayton, Ohio)
Published: November 26, 2024

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma.

Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma.

Journal: Cell death & disease
Published: November 26, 2024

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.

Journal: Liver cancer
Published: October 12, 2024

Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer.

Identification of PANoptosis-relevant subgroups and predicting signature to evaluate the prognosis and immune landscape of patients with biliary tract cancer.

Journal: Hepatology international
Published: April 24, 2024

Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.

Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.

Journal: Neoplasma
Published: August 06, 2023

Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.

Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.

Journal: Frontiers in immunology
Published: December 19, 2022
Showing 1-12 of 38

Last Updated: 09/26/2026